Strain | Serotype | Sequence type (ST)* | Phenotype† | Adhesion‡ | Invasion§ | Replication¶ |
---|---|---|---|---|---|---|
12-1-TI12 | O6: H31 | 127 | AIEC | 3.81±2.03 | 0.37±0.11 | 310.60±53.48 |
12-2-TI13 | O6: H31 | 127 | Non-AIEC | 5.61±2.31 | 0.72±0.13 | 50.24±24.33 |
18-3 TI5 | O25:H1 | 73 | Non AIEC | 0.25±0.10 | 0.04±0.01 | 179.30±76.61 |
18-4 TI12 | O25:H1 | 73 | Non AIEC | 0.48±0.26 | 0.04±0.02 | 143.09±25.45 |
33-1-TI5 | O16:H5 | 131 | AIEC | 6.68±2.28 | 0.10±0.03 | 867.09±77.11 |
36-1-TI13 | O83:H4 | 429 | Non AIEC | 0.39±0.17 | 0.01±0.00 | 402.45±86.68 |
39-2-TI18 | ** : ** | 95 | Non AIEC | 0.07±0.03 | 0.01±0.00 | 1241.09±597.43 |
41-2-TI13 | O17/O77:H41 | 720 | Non AIEC | 0.68±0.20 | 0.03±0.01 | 410.29±85.78 |
46-1-TI2 | O1:H7 | 95 | Non AIEC | 0.20±0.06 | 0.01±0.01 | 707.98±358.64 |
52-1-TI3 | O18:H7 | 95 | AIEC | 34.26±9.89 | 1.50±0.15 | 934.28±250.38 |
52-2-TI10 | O75:H5 | 550 | Non AIEC | 0.11±0.08 | 0.01±0.00 | 153.11±31.56 |
54-1-TI6 | O110:H27 | 1919 | Non AIEC | 9.30±5.13 | 0.07±0.03 | 408.36±65.09 |
55-1-AU4 | O25:H4 | 131 | Non AIEC | 0.11±0.04 | 0.03±0.02 | 162.92±82.29 |
55-1-TI19 | O25:H4 | 131 | Non AIEC | 0.05±0.05 | 0.03±0.01 | 325.74±164.91 |
57-3-TI5 | O75:H5 | 537 | AIEC | 2.73±1.07 | 0.14±0.03 | 723.55±65.60 |
60-1-TI1 | O75:H7 | 80 | AIEC | 7.08±1.35 | 0.13±0.06 | 333.25±107.54 |
61-1-TI1 | O18:H7 | 95 | AIEC | 54.63±16.65 | 1.89±0.70 | 869.90±211.49 |
62-2-TI6 | O1:H7 | 95 | Non AIEC | 1.24±0.33 | 0.14±0.02 | 90.74±35.52 |
63-1-TI1 | O50O2:H18 | 963 | Non AIEC | 1.43±0.63 | 0.03±0.00 | 158.22±42.48 |
69-1 AU1 | O46:H31 | 569 | Non AIEC | 0.66±0.15 | 0.07±0.03 | 79.02±12.65 |
69-1-TI1 | O46:H31 | 569 | Non-AIEC | 0.60±0.13 | 0.10±0.03 | 91.37±30.65 |
70-2-TI12 | O46:H31 | 569 | Non-AIEC | 1.22±0.58 | 0.06±0.01 | 45.49±5.68 |
72-6-Ti12 | O46:H31 | 569 | Non-AIEC | 1.05±0.06 | 0.03±0.00 | 73.82±17.73 |
CD 1IM 3 | O83:H6 | 2622 | Non-AIEC | 3.47±0.27 | 0.02±0.00 | 1163.70±203.59 |
CD 34 LN | O1:H7 | 95 | Non-AIEC | 0.14±0.06 | 0.02±0.00 | 458.485±105.69 |
CD 62 LN | O2:H4 | 95 | AIEC | 4.68±2.07 | 0.33±0.06 | 1686.33±307.68 |
H001 | O8:H10 | 681 | Non-AIEC | 1.19±0.02 | 0.02±0.00 | 708.12±55.32 |
H020 | O22:H1 | 73 | Non-AIEC | 1.33±0.07 | 0.08±0.04 | 1009.20±137.15 |
H223 | O2:H6 | 141 | AIEC | 9.03±2.55 | 0.46±0.23 | 435.23±108.95 |
H252 | O1:H7 | 95 | Non-AIEC | 3.47±0.20 | 0.09±0.04 | 74.23±30.72 |
H263 | O2:H7 | 95 | Non-AIEC | 0.30±0.03 | 0.01±0.00 | 398.51±93.69 |
H296 | O2:H7 | 95 | Non-AIEC | 0.45±0.04 | 0.00±0.00 | 792.33±78.74 |
H305 | O18:H7 | 95 | AIEC | 27.52±6.10 | 0.63±0.24 | 730.65±68.44 |
H397 | O1:H7 | 95 | Non-AIEC | 0.42±0.09 | 0.01±0.00 | 245.22±50.18 |
H413 | O18:H7 | 95 | Non-AIEC | 0.91±0.05 | 0.02±0.00 | 717.92±411.86 |
H461 | O18:H7 | 95 | Non-AIEC | 0.40±0.07 | 0.01±0.00 | 73.60±19.38 |
H504 | O18ac:H7 | 95 | AIEC | 3.28±1.78 | 0.28±0.03 | 330.81±80.68 |
H588 | ** :H5 | 126 | Non-AIEC | 3.38±1.39 | 0.04±0.00 | 1141.51±65.45 |
H660 | O1:H7 | 95 | Non-AIEC | 0.52±0.16 | 0.01±0.00 | 701.56±145.06 |
ED1a | O81:H27 | 452 | Non-AIEC | 0.25±0.07 | 0.05±0.01 | 68.34±30.95 |
LF82 | O83:H1 | 135 | AIEC | 62.83±5.08 | 12.23±2.01 | 227.81±61.37 |
K-12 | OR:H48 | 10 | Non-AIEC | 1.43±0.40 | 0.02±0.00 | 22.49±4.34 |
Results for adhesion, invasion and replication assays, data are means±SEM of independent experiments.
*Sequence type (ST) is based on the multilocus sequence type (MLST) scheme of Wirth et al.23
†Determination of E. coli strains as belonging to the AIEC pathovar was performed using the following criteria: (1) the ability to adhere to I-407 epithelial cells with an adhesion index equal or superior to 1 bacteria per cell, (2) the ability of the bacteria to invade I-407 with an invasion index equal or superior to 0.1% of the original inoculum, (3) the ability to survive and to replicate within THP-1 macrophages.
‡Mean number of bacteria per I-407 cell after 3 h of incubation.
§Mean percentage of the original inoculum after 1 h gentamicin treatment of infected I-407 cells.
¶Percentage of intracellular bacteria at 24 h post infection relative to the number after 1 h gentamicin treatment, defined as 100%.
**No O-antigen processing genes and/or H-antigen flagellin genes detected using the SeroType Finder tool (http://www.genomicepidemiology.org).
LN, lymph node.